SLCO1B1, ABCG2 and Rosuvastatin: SLCO1B1 Decreased Function

Decreased SLCO1B1 transporter function. Moderate risk of statin-induced myopathy with 40 mg based on SLCO1B1 alone.

Important Instructions: Please use ABCG2 phenotype to select the appropriate recommendation below.

ABCG2 Normal Function

Normal ABCG2 transporter function. Normal response expected based on ABCG2 alone.

Therapeutic Recommendation

  • Initiate standard dosing.

ABCG2 Decreased Function

Decreased ABCG2 transporter function. Increased chance for treatment success (i.e., lipid-lowering) based on ABCG2 alone.

Therapeutic Recommendation

  • Initiate standard dosing.

ABCG2 Poor Function

Little ABCG2 transporter function. Increased chance for treatment success (i.e., lipid-lowering) and potential risk for myopathy secondary to increased drug exposure based on ABCG2 alone.

Therapeutic Recommendation

  • Initiate ≤ 10 mg, if dose > 10 mg is needed, consider alternative statin or combination therapy.

Back to previous page